Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study

dc.creatorMonteiro, I
dc.creatorBahamondes, L
dc.creatorDiaz, J
dc.creatorPerrotti, M
dc.creatorPetta, C
dc.date2002
dc.dateMAY
dc.date2014-11-17T11:40:49Z
dc.date2015-11-26T16:42:42Z
dc.date2014-11-17T11:40:49Z
dc.date2015-11-26T16:42:42Z
dc.date.accessioned2018-03-28T23:27:20Z
dc.date.available2018-03-28T23:27:20Z
dc.identifierContraception. Elsevier Science Inc, v. 65, n. 5, n. 325, n. 328, 2002.
dc.identifier0010-7824
dc.identifierWOS:000176172800002
dc.identifier10.1016/S0010-7824(02)00283-4
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/57965
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/57965
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/57965
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1273341
dc.descriptionThe objective of this study was to evaluate the efficacy and performance, for LIP to I year, of air intrauterine system releasing 20 mug/day of levonorgestrel (LNG-IUS, Mirena) in the treatment of women with menorrhagia. It was a descriptive, prospective, non-comparative study. A 20 mug/day LNG-releasing-IUS was inserted on any day during bleeding to 44 women (between 24 and 49 years of age) who presented with menorrhagia after medical therapies had failed. Menstrual patterns were assessed, and hemoglobin concentrations were measured before LNG-IUS was inserted and at 3, 6, 9, and 12 months of use. The most common bleeding pattern at 3 months after insertion was spotting, and after 6, 9, and 12 months the majority of women presented with amenorrhea or oligomenorthea. Three women requested removal of the LNG-IUS because of spotting, and six women expelled it spontaneously. Hemoglobin levels were improved from 102 g/L to 123 and 128 g/L at 3 and 12 months, respectively, after insertion of the LNG-IUS (p < 0.01). At 12 months 79.5% of participants continued the use of LNG-IUS. In conclusion, LNG-IUS was an effective treatment for three out of four women with menorrhagia and could be an alternative treatment for women with menorrhagia who are either contraindicated for or refuse hysterectomy or endometrial ablation. (C) 2002 Elsevier Science Inc. All rights reserved.
dc.description65
dc.description5
dc.description325
dc.description328
dc.languageen
dc.publisherElsevier Science Inc
dc.publisherNew York
dc.publisherEUA
dc.relationContraception
dc.relationContraception
dc.rightsfechado
dc.rightshttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.sourceWeb of Science
dc.subjectintrauterine system
dc.subjectlevonorgestrel
dc.subjectmenorrhagia
dc.subjectmirena
dc.subjectTranscervical Endometrial Resection
dc.subjectQuality-of-life
dc.subjectRandomized Trial
dc.subjectAbdominal Hysterectomy
dc.subjectDevices
dc.subjectPerformance
dc.subjectManagement
dc.subjectCampinas
dc.subjectBrazil
dc.subjectAcid
dc.titleTherapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución